EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN GRANULOCYTIC COLONY-STIMULATING FACTOR IN TREATMENT OF GRANULOCYTOPENIA DEVELOPED DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS

Voprosy Sovremennoj Pediatrii. 2010;9(4):94-100

 

Journal Homepage

Journal Title: Voprosy Sovremennoj Pediatrii

ISSN: 1682-5527 (Print); 1682-5535 (Online)

Publisher: "Paediatrician" Publishers LLC

Society/Institution: The Union of Pediatricians of Russia

LCC Subject Category: Medicine: Pediatrics

Country of publisher: Russian Federation

Language of fulltext: English, Russian

Full-text formats available: PDF

 

AUTHORS

E.I. Alexeeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
S.I. Valieva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
T.M. Bzarova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.L. Semikina (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
K.B. Isaeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
A.O. Lisitsyn (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
R.V. Denisova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.G. Chistyakova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
T.V. Sleptsova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.V. Mitenko (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 8 weeks

 

Abstract | Full Text

<em>Treatment of patients with severe clinical course of juvenile rheumatoid arthritis (JRA) is difficult problem. During the last years genetically engineered biological drugs are used equally with traditional immunosuppressive agents in treatment of severe forms of juvenile arthritis. High effectiveness of these drugs can be accompanied with development of unfavorable effects, for example, febrile neutropenia. The article presents results of a study of effectiveness and safety of recombinant human granulocytic colony-stimulating factor — filgrastim (Leucostim) — in treatment of granulocytopenia developed during immunosuppressive therapy in 16 patients with JRA. It was shown that administration of filgrastim arrests leucopenia in 100% of patients and granulocytopenia — in 93% of patients in 24 hours after first injection. High effectiveness of drug was combined with good tolerability and safety.</em><br /><strong><em>Key words: children, treatment, granulocytopenia, filgrastim, juvenile rheumatoid arthritis.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii — </em></em>Current Pediatrics. – 2010;9(4):<em><span>94-100</span></em>)</em></span>